RxDoctor Payments Data

Curstina Jennings

Psychiatric/Mental Health · Norfolk, VANPI 1730728460

Payments from drug & device makers

$1,751in general payments, 2019–2025

Across 99 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$755
  • Supernus Pharmaceuticals, Inc.$340
  • Otsuka America Pharmaceutical, Inc.$131
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$122
  • Acadia Pharmaceuticals Inc$121
  • E.r. Squibb & Sons, L.L.C.$70
  • plus $213 from 7 others

What the payments were for

  • Food & beverage$1,751100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,751 in reported general payments places this provider in the 75th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$14,551
Medicare patients
20
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl59$84,112
CaplytaLumateperone Tosylate19$36,063
RexultiBrexpiprazole17$28,175
Aripiprazole65$3,581
Atomoxetine Hcl19$2,530
Temazepam18$1,745
Oxcarbazepine71$1,445
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine36$1,362
Quetiapine Fumarate153$1,346
Hydroxyzine Hcl93$1,030
Lurasidone Hcl12$931
Divalproex Sodium55$798
Mirtazapine64$782
Divalproex Sodium ErDivalproex Sodium29$749
Lamotrigine86$443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$755$84,11259 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$50$36,06319 claims
Otsuka America Pharmaceutical, Inc.Rexulti$131$28,17517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →